EE334 Cost-Effectiveness Analysis of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Greece
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.580
https://www.valueinhealthjournal.com/article/S1098-3015(22)02784-X/fulltext
Title :
EE334 Cost-Effectiveness Analysis of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Greece
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02784-X&doi=10.1016/j.jval.2022.09.580
First page :
Section Title :
Open access? :
No
Section Order :
10115